Myeloproliferative Disorder: Clinical Trials

22 trials for Myeloproliferative Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed, 2 recruiting, 1 active not recruiting, 1 unknown. 10 Phase 2, 4 Not applicable, 2 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 210Completed 8, Active not recruiting 1, Recruiting 1
Not applicable4Completed 4
Phase 12Completed 2
Phase 32Completed 2

Follow Myeloproliferative Disorder: new trials by email Literature Review of Myeloproliferative Disorder trials Research Report on Myeloproliferative Disorder

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Polycythemia Vera, ET (Essential Thrombocythemia)
RecruitingMPN Research Foundation50002025-09-262026-01-23
Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia
Gene sequencing - Myeloproliferative Disorder
UnknownCentre Hospitalier Universitaire de Nīmes302023-10-012024-02-07
Cord Blood Transplant in Adults With Blood Cancers
Conditioning Chemotherapy, Cord blood graft - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center172023-05-222026-10-23
Haplo Peripheral Blood Sct In GVHD Prevention
FLUDARABINE, CYCLOPHOSPHAMIDE, TBI - GVHD, AML
Phase 1CompletedZachariah Michael DeFilipp252020-08-142025-07-20
Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.
Non-invasive diagnosis score - Myeloproliferative Disorder, Essential Thrombocythemia
Not applicableCompletedUniversity Hospital, Angers1332019-07-302024-12-30
Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms
Aprepitant 80 mg, Hydroxyzine 25mg, Placebo of Hydroxyzine - Myeloproliferative Disorder, Aquagenic Pruritus
Phase 3CompletedUniversity Hospital, Brest632019-04-162025-12-03
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
Thymoglobulin, Melphalan, Fludarabine - Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes
Phase 2RecruitingUniversity of Liege1142019-02-042022-10-12
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Total body irradiation (TBI), Anti-thymocyte globulin (ATG), Tacrolimus - Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 2CompletedStanford University222018-11-052023-12-12
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase
USDA Diet, Mediterranean Diet - Myeloproliferative Disorder, Myeloproliferative Syndrome
Not applicableCompletedUniversity of California, Irvine302018-10-012020-03-24
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
Phase 3CompletedDartmouth-Hitchcock Medical Center212018-03-282026-07-17
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Total Body Irradiation, Cyclosporine, Mycophenolate Mofetil - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Phase 2CompletedMemorial Sloan Kettering Cancer Center462018-02-072026-05-26
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
Isavuconazole - Hematologic Malignancy, Myeloproliferative Disorder
Phase 2CompletedMemorial Sloan Kettering Cancer Center992017-05-042025-05-16
Clinical Characteristics of Aquagenic Pruritus in Patients With Myeloproliferative Neoplasms
Myeloproliferative Disorder
CompletedUniversity Hospital, Brest702013-07-172019-07-01
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
Graft Manipulation (CD34+ Selection) - MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder
Phase 1 / Phase 2CompletedNational Heart, Lung, and Blood Institute (NHLBI)412013-05-292020-07-21
Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases
echocardiography, right heart catheterisation - Myeloproliferative Disorder, Myelodysplastic Syndromes
CompletedMedical University of Graz862009-04-012012-03-09
Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders
Myeloproliferative Disorder, MDS
CompletedCorewell Health West602008-04-012023-07-27
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
IL-2 - Acute Lymphoblastic Leukemia, ALL
Phase 2CompletedBaylor College of Medicine252007-06-012018-05-04
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Bevacizumab, Carboplatin, Gemcitabine - Myeloproliferative Disorder, Urothelial Carcinoma
Phase 2CompletedMemorial Sloan Kettering Cancer Center512006-05-012016-01-22
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF - AML, ALL
Phase 2CompletedBeth Israel Deaconess Medical Center252002-12-012016-07-18
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Fludarabine, Melphalan, Stem cells - Acute Myelogenous Leukemia, Lymphoid Leukemia
Phase 2CompletedUniversity of Chicago2042001-11-012016-11-22

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Myeloproliferative Disorders (22)  ·  Myelodysplastic Syndromes (10)  ·  Leukemia, Myeloid, Acute (9)  ·  Lymphoma, Non-Hodgkin (9)  ·  Hodgkin Disease (8)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (6)  ·  Primary Myelofibrosis (6)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (5)  ·  Polycythemia Vera (4)  ·  Anemia, Aplastic (3)  ·  Blast Crisis (3)  ·  Hematologic Neoplasms (3)  ·  Lymphoma (3)  ·  Multiple Myeloma (3)

Broader conditions

Bone Marrow Diseases (22)  ·  Hematologic Diseases (22)  ·  Hemic and Lymphatic Diseases (22)  ·  Neoplasms (14)  ·  Neoplasms by Histologic Type (14)  ·  Pathologic Processes (12)  ·  Pathological Conditions, Signs and Symptoms (12)  ·  Immune System Diseases (11)  ·  Immunoproliferative Disorders (11)  ·  Lymphatic Diseases (11)  ·  Lymphoproliferative Disorders (11)  ·  Leukemia (10)  ·  Leukemia, Myeloid (10)  ·  Chronic Disease (9)  ·  Disease Attributes (9)

Interventions

fludarabine (6)  ·  Cyclophosphamide (4)  ·  Melphalan (4)  ·  Mycophenolic Acid (4)  ·  Whole-Body Irradiation (3)  ·  fludarabine phosphate (3)  ·  Alemtuzumab (2)  ·  Cyclosporine (2)  ·  Granulocyte Colony-Stimulating Factor (2)  ·  Tacrolimus (2)  ·  thymoglobulin (2)  ·  Antilymphocyte Serum (1)  ·  Aprepitant (1)  ·  Aspirin (1)  ·  Base Sequence (1)

Sponsors

Memorial Sloan Kettering Cancer Center (4)  ·  University Hospital, Brest (2)  ·  Baylor College of Medicine (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Centre Hospitalier Universitaire de Nīmes (1)  ·  Corewell Health West (1)  ·  Dartmouth-Hitchcock Medical Center (1)  ·  MPN Research Foundation (1)  ·  Medical University of Graz (1)  ·  National Heart, Lung, and Blood Institute (NHLBI) (1)  ·  Stanford University (1)  ·  University Hospital, Angers (1)  ·  University of California, Irvine (1)  ·  University of Cambridge (1)  ·  University of Chicago (1)

Countries

United States (15)  ·  France (3)  ·  Austria (1)  ·  Belgium (1)  ·  United Kingdom (1)

Top investigators

Andrew Artz, MD (1)  ·  Angela G Fleischman, MD PhD (1)  ·  Ann Jakubowski, MD (1)  ·  Anthony R Green, Prof (1)  ·  Arthur S Alberts, PhD (1)  ·  Claire Harrison, Dr (1)  ·  Damiano Rondelli, MD (1)  ·  David E Avigan, MD (1)  ·  David F McDermott, MD (1)  ·  Dean Bajorin, MD (1)  ·  Horst Olschewski, MD (1)  ·  Ioannis Politikos, MD (1)

Results publications

PMID 24573552, PMID 27291777, PMID 30153096, PMID 34923994, PMID 37877698, PMID 40423982

NIH funding

2017 (1), 2018 (1)